josé luis pires sars-cov-2 report 29 may 2020 · 5/29/2020 · may 2020 confidential hovione ©...

29 May 2020SARS-Cov-2 ReportJosé Luis Pires

Confidential Hovione © 2020May 2020 2

SARS-Cov-2

➢ Confirmed cases by Country

➢ Deaths by Country

➢ Total confirmed Covid-19 cases and deaths per million people

➢ Portugal, Loures, Macau, New Jersey, Ireland - Cases by day and Total

➢ Reported infections per 1 million people for select countries with over 100 reported cases

➢ New cases vs 7-day average

➢ Cases Curve Simulator

➢ The latest coronavirus updates and developments impacting the global pharmaceutical supply

chain

Contents


Coronavirus (SARS-CoV-2 / Covid-19) – Confirmed cases by countryNote: Selected Countries, sorted by # of cases

1,4731,6561,8051,8512,2452,9063,0763,8414,0086,7437,1737,6297,6438,41111,40211,71214,70215,58816,62016,62816,88724,84130,79631,59633,86035,72746,15257,849

84,10689,976

160,979165,829

182,450186,364

231,732237,906

270,508379,051

438,2381,721,750

0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000

SloveniaLithuania

IcelandEstoniaCroatiaGreece

ThailandHungary

LuxembourgFinland

AustraliaMalaysiaMoroccoNorway

KoreaDenmarkArgentina

PhilippinesJapan

AustriaIsrael

IrelandSwitzerland

PortugalSingapore

SwedenNetherlands

BelgiumChina

CanadaTurkey

IndiaGermany

FranceItaly

SpainUK

RussiaBrazil

US

Last Updated at 29 May 2020, 8:32 AM

by the Center for Systems Science and Engineering

at Johns Hopkins University

Sourc

e:

htt

ps:/

/gis

anddata

.maps.a

rcgis

.com

/apps/o

psdashboard

/in

dex.h

tml#

/bda759474

0fd

40

29

94

23

46

7b

48

e9

ecf6

17 April 202024 April 20201 May 20208 May 202015 May 202022 May 202029 May 2020

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6


Total confirmed Covid-19 cases per million people


Coronavirus (SARS-CoV-2 / Covid-19) – Deaths by CountryNote: Selected Countries, sorted by # of cases

101,617

26,754

4,142

37,919

27,119

33,14228,665

8,4724,7134,461

6,9824,638

9,3885,9224,266

23 1,3691,9191,639284 668 881 921 508 568 269 236 202 115 103 313 110 517 57 175 102 66 10 68 1080

20,000

40,000

60,000

80,000

100,000

120,000

Source: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

Last Updated at 29 May 2020, 8:32 AM

by the Center for Systems Science and Engineering

at Johns Hopkins University



Total confirmed Covid-19 deaths per million people


Coronavirus (SARS-CoV-2 / COVID 19) – Portugal - Confirmed cases by day

2 2 2 3 4 8 9 9 2181934577686117

194143

235260

320

460

302

633

549

724

902

792

446

1035

808783

852

638

754

452

712699

815

1516

515

598

349

514

643

750

181

663

521

657

516

603

371

444

595

472

163

295

183

540

306

0

92

242

178

480533553

138175

98

234219187

264227226

173223228252

288271

152165219

285304350

0

200

400

600

800

1000

1200

1400

1600

2.m

ar

3.m

ar

4.m

ar

5.m

ar

6.m

ar

7.m

ar

8.m

ar

9.m

ar

10

.ma

r1

1.m

ar

12

.ma

r1

3.m

ar

14

.ma

r1

5.m

ar

16

.ma

r1

7.m

ar

18

.ma

r1

9.m

ar

20

.ma

r2

1.m

ar

22

.ma

r2

3.m

ar

24

.ma

r2

5.m

ar

26

.ma

r2

7.m

ar

28

.ma

r2

9.m

ar

30

.ma

r3

1.m

ar

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r1

1.a

pr

12

.ap

r1

3.a

pr

14

.ap

r1

5.a

pr

16

.ap

r1

7.a

pr

18

.ap

r1

9.a

pr

20

.ap

r2

1.a

pr

22

.ap

r2

3.a

pr

24

.ap

r2

5.a

pr

26

.ap

r2

7.a

pr

28

.ap

r2

9.a

pr

30

.ap

r1

.ma

y2

.ma

y3

.ma

y4

.ma

y5

.ma

y6

.ma

y7

.ma

y8

.ma

y9

.ma

y1

0.m

ay

11

.ma

y1

2.m

ay

13

.ma

y1

4.m

ay

15

.ma

y1

6.m

ay

17

.ma

y1

8.m

ay

19

.ma

y2

0.m

ay

21

.ma

y2

2.m

ay

23

.ma

y2

4.m

ay

25

.ma

y2

6.m

ay

27

.ma

y2

8.m

ay

29

.ma

y

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

** - recalculated numbers

https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/


Coronavirus (SARS-CoV-2 / COVID 19) – Portugal - Total cases by day

2 4 6 9 13 21 30 39 41 59 781121692453314486427851,0201,2801,6002,0602,362

2,9953,544

4,2685,170

5,9626,408

7,4438,251

9,0349,886

10,52411,278

11,73012,452

13,14113,956

15,47215,987

16,58516,93417,448

18,09118,84119,022

19,68520,206

20,86321,379

21,98222,35322,797

23,39223,86424,02724,32224,505

25,05625,35125,19025,28225,52425,70226,182

26,71527,26827,40627,58127,67927,91328,13228,31928,58328,81029,03629,20929,43229,66029,912

30,200

30,47130,62330,78831,00731,29231,596

31,946

0%

100%

50%50%

44%

62%

43%

30%

5%

44%

32%

44%

51%

45%

35%35%

43%

22%

30%25%

25%29%

15%

27%

18%20%21%

15%

7%

16%

11%9%9%6%7%

4%6%6%6%

11%

3%4%2%3%4%4%1%

3%3%3%2%3%2%2%3%2%1%1%1%2%1% 0%1%1%2%2%2%1%1%0%1%1%1%1%1%1%1%1%1%1%1%1%0%1%1%1%1%1%

0%

20%

40%

60%

80%

100%

120%

0

5000

10000

15000

20000

25000

30000

35000

# of cases % increase




Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – Hospital: Stable vs ICU

0 0 0 0 9 132130384057

107107114139139

206

8989126

156169201203

276

191

354

418

486

571

627

726

10421058107510841099

11801211

117311791175117711871227

1200

1302128412531243

12081172

1146

10951068

10401005995

936980968

892855856

813818838

874842

815797805

709692680673657649628629

609608576

550536531513510529

0 0 0 0 0 0 0 0 0 0 0 0 0 10 9 18172020263541474861617189

136164

188230240245251267270271

245241226233228188

218208229222228224215213207204188186182176172169172154150144143134136135127120112112113103108112115108105101939284807872716666

0

200

400

600

800

1000

1200

1400

1.m

ar

2.m

ar

3.m

ar

4.m

ar

5.m

ar

6.m

ar

7.m

ar

8.m

ar

9.m

ar

10

.ma

r1

1.m

ar

12

.ma

r1

3.m

ar

14

.ma

r1

5.m

ar

16

.ma

r1

7.m

ar

18

.ma

r1

9.m

ar

20

.ma

r2

1.m

ar

22

.ma

r2

3.m

ar

24

.ma

r2

5.m

ar

26

.ma

r2

7.m

ar

28

.ma

r2

9.m

ar

30

.ma

r3

1.m

ar

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r1

1.a

pr

12

.ap

r1

3.a

pr

14

.ap

r1

5.a

pr

16

.ap

r1

7.a

pr

18

.ap

r1

9.a

pr

20

.ap

r2

1.a

pr

22

.ap

r2

3.a

pr

24

.ap

r2

5.a

pr

26

.ap

r2

7.a

pr

28

.ap

r2

9.a

pr

30

.ap

r1

.ma

y2

.ma

y3

.ma

y4

.ma

y5

.ma

y6

.ma

y7

.ma

y8

.ma

y9

.ma

y1

0.m

ay

11

.ma

y1

2.m

ay

13

.ma

y1

4.m

ay

15

.ma

y1

6.m

ay

17

.ma

y1

8.m

ay

19

.ma

y2

0.m

ay

21

.ma

y2

2.m

ay

23

.ma

y2

4.m

ay

25

.ma

y2

6.m

ay

27

.ma

y2

8.m

ay

29

.ma

y

Hospital Stable Hospital ICU




Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – Deaths vs Recoveries

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 2 3 6 12142333436076100119140160187209246266295311345380409435470504535567599629657687714735762785820854880903928948973989100710231043106310741089110511141126113511441163117511841190120312181231124712631277

1289

130213161330134213561369

1383

0 0 0 0 0 0 0 0 0 0 0 1 1 1 2 3 3 3 3 5 5 5 142222434343434343436868757514018419620523326627727734738349351961061061091711461201122812771329135713891470151916471671168917121743

2076225824222499254925493013318231983328

3822

4636

6430643164526452

75907705

1754917822

180961834918637

18911

0

2000

4000

6000

8000

10000

12000

14000

16000

18000

20000

1.m

ar

2.m

ar

3.m

ar

4.m

ar

5.m

ar

6.m

ar

7.m

ar

8.m

ar

9.m

ar

10

.ma

r1

1.m

ar

12

.ma

r1

3.m

ar

14

.ma

r1

5.m

ar

16

.ma

r1

7.m

ar

18

.ma

r1

9.m

ar

20

.ma

r2

1.m

ar

22

.ma

r2

3.m

ar

24

.ma

r2

5.m

ar

26

.ma

r2

7.m

ar

28

.ma

r2

9.m

ar

30

.ma

r3

1.m

ar

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r1

1.a

pr

12

.ap

r1

3.a

pr

14

.ap

r1

5.a

pr

16

.ap

r1

7.a

pr

18

.ap

r1

9.a

pr

20

.ap

r2

1.a

pr

22

.ap

r2

3.a

pr

24

.ap

r2

5.a

pr

26

.ap

r2

7.a

pr

28

.ap

r2

9.a

pr

30

.ap

r1

.ma

y2

.ma

y3

.ma

y4

.ma

y5

.ma

y6

.ma

y7

.ma

y8

.ma

y9

.ma

y1

0.m

ay

11

.ma

y1

2.m

ay

13

.ma

y1

4.m

ay

15

.ma

y1

6.m

ay

17

.ma

y1

8.m

ay

19

.ma

y2

0.m

ay

21

.ma

y2

2.m

ay

23

.ma

y2

4.m

ay

25

.ma

y2

6.m

ay

27

.ma

y2

8.m

ay

29

.ma

y

Total Confirmed Deaths Total Confirmed Recoveries




Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – 28 May 2020

Confirmed Cases - Total Deaths - Total

Source: Expresso - https://expresso.pt/coronavirus/2020-05-15-Covid-19.-O-maior-aumento-de-novos-casos-dos-ultimos-sete-dias-o-surto-em-Portugal--em-graficos-e-mapas-

Confirmed Cases

https://expresso.pt/coronavirus/2020-05-15-Covid-19.-O-maior-aumento-de-novos-casos-dos-ultimos-sete-dias-o-surto-em-Portugal--em-graficos-e-mapas-


Coronavirus (SARS-CoV-2 / COVID 19) – Loures - Confirmed cases by day

4

0 0

29

78

12

17

8 89

4

13

4

2021

12

5 5

119

109

11

6

3

32

0

9

21

11

0 0

54

17

7 78

2

10

33

11

0

33

8

2

29

23

1715

13

8

30

14

22

37

56

31

17

9

35

31

40

48

0

10

20

30

40

50

60

24

.ma

r

25

.ma

r

26

.ma

r

27

.ma

r

28

.ma

r

29

.ma

r

30

.ma

r

31

.ma

r

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r

11

.ap

r

12

.ap

r

13

.ap

r

14

.ap

r

15

.ap

r

16

.ap

r

17

.ap

r

18

.ap

r

19

.ap

r

20

.ap

r

21

.ap

r

22

.ap

r

23

.ap

r

24

.ap

r

25

.ap

r

26

.ap

r

27

.ap

r

28

.ap

r

29

.ap

r

30

.ap

r

1.m

ay

2.m

ay

3.m

ay

4.m

ay

5.m

ay

6.m

ay

7.m

ay

8.m

ay

9.m

ay

10

.ma

y

11

.ma

y

12

.ma

y

13

.ma

y

14

.ma

y

15

.ma

y

16

.ma

y

17

.ma

y

18

.ma

y

19

.ma

y

20

.ma

y

21

.ma

y

22

.ma

y

23

.ma

y

24

.ma

y

25

.ma

y

26

.ma

y

27

.ma

y

28

.ma

y

29

.ma

y




Coronavirus (SARS-CoV-2 / COVID 19) – Loures - Total cases by day

24 28 28 2857 64 72 84

101109117126130131134138158

179191196201212221231240251257260292292301303304315315315

369386393400408410420

453464464497505507

536559

576591604612

642656

678

715

771802

819828

863894

934

982

17%

0%0%

104%

12%13%17%

20%

8%7%8%

3%1%2%3%

14%13%7%3%

3%5%4%5%4%5%

2%1%

12%

0%3%

1%0%4%

0%0%

17%

5%2%2%2%0%

2%

8%

2%0%

7%

2%0%

6%4%3%3%2%1%5%

2%3%5%

8%4%

2%1%4%4%4%5%

0%

20%

40%

60%

80%

100%

120%

0

200

400

600

800

1000

1200

24

.ma

r

25

.ma

r

26

.ma

r

27

.ma

r

28

.ma

r

29

.ma

r

30

.ma

r

31

.ma

r

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r

11

.ap

r

12

.ap

r

13

.ap

r

14

.ap

r

15

.ap

r

16

.ap

r

17

.ap

r

18

.ap

r

19

.ap

r

20

.ap

r

21

.ap

r

22

.ap

r

23

.ap

r

24

.ap

r

25

.ap

r

26

.ap

r

27

.ap

r

28

.ap

r

29

.ap

r

30

.ap

r

1.m

ay

2.m

ay

3.m

ay

4.m

ay

5.m

ay

6.m

ay

7.m

ay

8.m

ay

9.m

ay

10

.ma

y

11

.ma

y

12

.ma

y

13

.ma

y

14

.ma

y

15

.ma

y

16

.ma

y

17

.ma

y

18

.ma

y

19

.ma

y

20

.ma

y

21

.ma

y

22

.ma

y

23

.ma

y

24

.ma

y

25

.ma

y

26

.ma

y

27

.ma

y

28

.ma

y

29

.ma

y





Coronavirus (SARS-CoV-2 / COVID 19) – Lisbon - Confirmed cases by day

12

97

0

82

228

39

-128

4148

40

2027

18

55

1924

54

1623

15

41

16

3424

135

22

85

24

97

5

75

60

70

34

1831

71

0 012

4841

3224

112

54

202436

48

1924

56

28303139

31

5

24

483634

-150

-100

-50

0

50

100

150

200

250

24

.ma

r

25

.ma

r

26

.ma

r

27

.ma

r

28

.ma

r

29

.ma

r

30

.ma

r

31

.ma

r

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r

11

.ap

r

12

.ap

r

13

.ap

r

14

.ap

r

15

.ap

r

16

.ap

r

17

.ap

r

18

.ap

r

19

.ap

r

20

.ap

r

21

.ap

r

22

.ap

r

23

.ap

r

24

.ap

r

25

.ap

r

26

.ap

r

27

.ap

r

28

.ap

r

29

.ap

r

30

.ap

r

1.m

ay

2.m

ay

3.m

ay

4.m

ay

5.m

ay

6.m

ay

7.m

ay

8.m

ay

9.m

ay

10

.ma

y

11

.ma

y

12

.ma

y

13

.ma

y

14

.ma

y

15

.ma

y

16

.ma

y

17

.ma

y

18

.ma

y

19

.ma

y

20

.ma

y

21

.ma

y

22

.ma

y

23

.ma

y

24

.ma

y

25

.ma

y

26

.ma

y

27

.ma

y

28

.ma

y

29

.ma

y




Coronavirus (SARS-CoV-2 / COVID 19) – Lisbon - Total cases by day

175187

284284

366

594633

505546

594634654681699

754773797851867890905

9469629961,0201,0331,0381,060

1,1451,169

1,2661,271

1,3461,4061,4131,413

1,4471,4651,496

1,5671,5671,5671,5791,627

1,6681,7001,7241,7351,737

1,7911,8111,8351,871

1,9191,9381,9622,0182,046

2,076

2,1072,146

2,1772,1822,2062,254

2,290

2,324

7%

52%

0%

29%

62%

7%

-20%

8%9%7%

3%4%3%

8%

3%3%7%2%

3%

2%5%

2%4%2%1%0%

2%

8%

2%

8%

0%

6%4%

0%0%2%1%2%

5%

0%0%1%3%3%2%1%1%0%

3%1%1%2%3%

1%1%3%1%1%1%2%1%0%1%2%2%1%

-30%

-20%

-10%

0%

10%

20%

30%

40%

50%

60%

70%

0

500

1000

1500

2000

2500

24

.ma

r

25

.ma

r

26

.ma

r

27

.ma

r

28

.ma

r

29

.ma

r

30

.ma

r

31

.ma

r

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r

11

.ap

r

12

.ap

r

13

.ap

r

14

.ap

r

15

.ap

r

16

.ap

r

17

.ap

r

18

.ap

r

19

.ap

r

20

.ap

r

21

.ap

r

22

.ap

r

23

.ap

r

24

.ap

r

25

.ap

r

26

.ap

r

27

.ap

r

28

.ap

r

29

.ap

r

30

.ap

r

1.m

ay

2.m

ay

3.m

ay

4.m

ay

5.m

ay

6.m

ay

7.m

ay

8.m

ay

9.m

ay

10

.ma

y

11

.ma

y

12

.ma

y

13

.ma

y

14

.ma

y

15

.ma

y

16

.ma

y

17

.ma

y

18

.ma

y

19

.ma

y

20

.ma

y

21

.ma

y

22

.ma

y

23

.ma

y

24

.ma

y

25

.ma

y

26

.ma

y

27

.ma

y

28

.ma

y

29

.ma

y





Coronavirus (SARS-CoV-2 / COVID 19) – New Jersey - Confirmed cases by

day

1 0 3 2 5 4 8 6 2119298089160

315148

437587

930831

727

2474

1949

22992262

3347

2196

36493489

43724229

3382

3663

3361

3088

374836273563

3733

3219

4059

2625

4391

3150

2953

3881

35053581

3478

4124

2207

3327

3515

2150

2668

2408238825382527

3027

1525

2324

1297

17451819

1631

14471413

798817

1144120111841245

1705

974

1386

1073

1247

385

1050938

672

864

1187

0

500

1000

1500

2000

2500

3000

3500

4000

4500

5000

5.m

ar

6.m

ar

7.m

ar

8.m

ar

9.m

ar

10

.ma

r

11

.ma

r

12

.ma

r

13

.ma

r

14

.ma

r

15

.ma

r

16

.ma

r

17

.ma

r

18

.ma

r

19

.ma

r

20

.ma

r

21

.ma

r

22

.ma

r

23

.ma

r

24

.ma

r

25

.ma

r

26

.ma

r

27

.ma

r

28

.ma

r

29

.ma

r

30

.ma

r

31

.ma

r

1.a

pr

2.a

pr

3.a

pr

4.a

pr

5.a

pr

6.a

pr

7.a

pr

8.a

pr

9.a

pr

10

.ap

r

11

.ap

r

12

.ap

r

13

.ap

r

14

.ap

r

15

.ap

r

16

.ap

r

17

.ap

r

18

.ap

r

19

.ap

r

20

.ap

r

21

.ap

r

22

.ap

r

23

.ap

r

24

.ap

r

25

.ap

r

26

.ap

r

27

.ap

r

28

.ap

r

29

.ap

r

30

.ap

r

1.m

ay

2.m

ay

3.m

ay

4.m

ay

5.m

ay

6.m

ay

7.m

ay

8.m

ay

9.m

ay

10

.ma

y

11

.ma

y

12

.ma

y

13

.ma

y

14

.ma

y

15

.ma

y

16

.ma

y

17

.ma

y

18

.ma

y

19

.ma

y

20

.ma

y

21

.ma

y

22

.ma

y

23

.ma

y

24

.ma

y

25

.ma

y

26

.ma

y

27

.ma

y

28

.ma

y

Source: https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html

https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html


Coronavirus (SARS-CoV-2 / COVID 19) – New Jersey - Total cases by day

1 0 4 6 111523295069981782674277428901,3271,9142,8443,6754,4026,8768,825

11,12413,386

16,63618,69622,255

25,59029,895

34,12437,505

41,09044,416

47,43751,027

54,58858,151

61,85064,584

68,82471,030

75,31778,467

81,42085,301

88,80692,387

95,86599,989

102,196105,523

109,038111,188113,856

116,264118,652

121,190123,717

126,744128,269130,593131,890133,635135,454137,085138,532139,945140,743141,560142,704143,905145,089146,334148,039149,013150,399

151,472152,719153,104154,154155,092155,764156,628

157,815

50%

83%

36%

53%

26%

72%

38%

42%

82%

50%

60%

74%

20%

49%

44%

49%

29%

20%

56%

28%26%

20%

24%

12%

19%

15%17%

14%

10%10%8%7%8%7%7%6%

4%7%

3%6%

4%4%5%4%4%4%4%2%3%3%

2%2%2%2%2%2%2%1%2%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%0%1%1%0%1%1%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

0

20000

40000

60000

80000

100000

120000

140000

160000

1800005

.ma

r6

.ma

r7

.ma

r8

.ma

r9

.ma

r1

0.m

ar

11

.ma

r1

2.m

ar

13

.ma

r1

4.m

ar

15

.ma

r1

6.m

ar

17

.ma

r1

8.m

ar

19

.ma

r2

0.m

ar

21

.ma

r2

2.m

ar

23

.ma

r2

4.m

ar

25

.ma

r2

6.m

ar

27

.ma

r2

8.m

ar

29

.ma

r3

0.m

ar

31

.ma

r1

.ap

r2

.ap

r3

.ap

r4

.ap

r5

.ap

r6

.ap

r7

.ap

r8

.ap

r9

.ap

r1

0.a

pr

11

.ap

r1

2.a

pr

13

.ap

r1

4.a

pr

15

.ap

r1

6.a

pr

17

.ap

r1

8.a

pr

19

.ap

r2

0.a

pr

21

.ap

r2

2.a

pr

23

.ap

r2

4.a

pr

25

.ap

r2

6.a

pr

27

.ap

r2

8.a

pr

29

.ap

r3

0.a

pr

1.m

ay

2.m

ay

3.m

ay

4.m

ay

5.m

ay

6.m

ay

7.m

ay

8.m

ay

9.m

ay

10

.ma

y1

1.m

ay

12

.ma

y1

3.m

ay

14

.ma

y1

5.m

ay

16

.ma

y1

7.m

ay

18

.ma

y1

9.m

ay

20

.ma

y2

1.m

ay

22

.ma

y2

3.m

ay

24

.ma

y2

5.m

ay

26

.ma

y2

7.m

ay

28

.ma

y


Source: https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html

https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html


Coronavirus (SARS-CoV-2 / COVID 19) – Macau - Confirmed cases by day

11

00

3

2

00000

1

0

2

00000000000000000000000000000000000000

111

22

11

2

5

22

3

22

11

2

00

111

00

1

0

0

1

2

3

4

5

6

Source: https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt

51 days since last reported case

https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt


Coronavirus (SARS-CoV-2 / COVID 19) – Macau - Total cases by day

1 12 2

5

7 7 7 7 7 78 8

10101010101010101010101010101010101010101010101010101010101010101010101010101011

1213

15

1718

19

21

26

28

3031

32

3738

39

41414142

43444444

45

0

5

10

15

20

25

30

35

40

45

50

23

.ja

n

25

.ja

n

27

.ja

n

29

.ja

n

31

.ja

n

2.f

ev

4.f

ev

6.f

ev

8.f

ev

10

.fe

v

12

.fe

v

14

.fe

v

16

.fe

v

18

.fe

v

20

.fe

v

22

.fe

v

24

.fe

v

26

.fe

v

28

.fe

v

1.m

ar

3.m

ar

5.m

ar

7.m

ar

9.m

ar

11

.ma

r

13

.ma

r

15

.ma

r

17

.ma

r

19

.ma

r

21

.ma

r

23

.ma

r

25

.ma

r

27

.ma

r

29

.ma

r

31

.ma

r

2.a

pr

4.a

pr

6.a

pr

8.a

pr

10

.ap

r

12

.ap

r

14

.ap

r

16

.ap

r

18

.ap

r

20

.ap

r

22

.ap

r

24

.ap

r

26

.ap

r

28

.ap

r

30

.ap

r

2.m

ay

4.m

ay

6.m

ay

8.m

ay

10

.ma

y

12

.ma

y

14

.ma

y

16

.ma

y

18

.ma

y

20

.ma

y

22

.ma

y

24

.ma

y

26

.ma

y

28

.ma

y

# of cases

Source: https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt

51 days since last reported case

https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt


Coronavirus (SARS-CoV-2 / COVID 19) – Ireland - Confirmed cases by day

1 0 0 1 4 7 5 1 2 31092720

394054

6974

191

126102

121

219204

235255

302294

200

295325

212

402424

331

390370

345365

500480

553

430

527548

657629

597630

445

401388

631

936

577

377

701

386

229

376359

221

343330

266

211

265

137156

219236

139107

159

426

129

9264

88

516476

115

765759

37

7346

Source: https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96

https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96


Coronavirus (SARS-CoV-2 / COVID 19) – Ireland - Total cases by day

1 0 3 6 1318192124344370901291692232923665576837859061,1251,3291,5641,8192,1212,4152,6152,9103,2353,4473,849

4,3734,6044,9945,3645,7096,074

6,5747,054

8,9289,655

10,64711,479

12,54713,271

13,98014,758

15,25115,652

16,04016,671

17,60718,184

18,56119,262

19,64819,87720,25320,61220,83321,17621,50621,77221,98322,24822,38522,54122,76022,99623,13523,24223,40123,827

23,95624,04824,11224,20024,25124,315

24,391

24,50624,58224,63924,69824,73524,803

24,841

100%

117%

38%

6%

11%14%

42%

26%

63%

29%

43%31%

32%31%

25%

52%

23%

15%15%

24%

18%18%16%17%14%

8%11%11%

7%

12%14%

5%8%7%6%6%8%7%

27%

8%10%

8%9%6%5%6%

3%3%2%4%6%3%2%4%2%1%2%2%1%2%2%1%1%1%1%1%1%1%1%0%1%2%1%0%0%0%0%0%0%0%0%0%0%0%0%0%

0%

20%

40%

60%

80%

100%

120%

140%

0

5000

10000

15000

20000

25000

30000

29

.fe

v

2.m

ar

4.m

ar

6.m

ar

8.m

ar

10

.ma

r

12

.ma

r

14

.ma

r

16

.ma

r

18

.ma

r

20

.ma

r

22

.ma

r

24

.ma

r

26

.ma

r

28

.ma

r

30

.ma

r

1.a

pr

3.a

pr

5.a

pr

7.a

pr

9.a

pr

11

.ap

r

13

.ap

r

15

.ap

r

17

.ap

r

19

.ap

r

21

.ap

r

23

.ap

r

25

.ap

r

27

.ap

r

29

.ap

r

1.m

ay

3.m

ay

5.m

ay

7.m

ay

9.m

ay

11

.ma

y

13

.ma

y

15

.ma

y

17

.ma

y

19

.ma

y

21

.ma

y

23

.ma

y

25

.ma

y

27

.ma

y


Source: https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96

https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96


Global infection snapshot: latest infection trends, declines from peak

infection levels and country GDP (size of bubble)

May 20, 2020 May 27, 2020


New daily infections per 1 million people

May 20, 2020 May 27, 2020


Infection and mortality for US states


Daily deaths of

patients diagnosed

with coronavírus

(7-day average)

So

urc

e: h

ttp

s:/

/ww

w.f

t.co

m/c

on

ten

t/a

26fb

f7e

-48f8

-11

ea-a

eb3

-955

839

e06

441

https://www.ft.com/content/a26fbf7e-48f8-11ea-aeb3-955839e06441


New

cases v

s

7-d

ay a

vera

ge

Country/CityTotal

cases

Total

deaths

New daily cases:

reported on 28 May

New daily cases:

7-day avg

New cases vs

7-day average

28 May 2020

C

o

l

New cases vs

7-day average

21 May 2020

C

o

l

u

New cases vs

7-day average

14 May 2020

C

o

l

u

New cases vs

7-day average

8 May 20202

C

o

l

u

New cases vs

7-day average

30 April 2020

C

o

l

u

New cases vs

7-day average

23 April 20202

C

o

l

u

New cases vs

7-day average

16 April 20202

C

o

l

u

New cases vs

7-day average

9 April 2020

C

o

l

u

New cases vs

7-day average

2 April 2020

Loures 934 40 31 Up Up Up Down Up Down Up Up Down

Lisbon 2,290 36 31 Up Down Up Up Down Up Up Down Up

New Jersey 157,815 1,187 906 Up Down Down Down Down Up Up Up Up

Cork 1,458

Argentina 14,702 508 600 631 Down Up Up Up Up Up Up Down Down

Australia 7,173 103 6 9 Down Down Down Up Down Down Down Down Down

Austria 16,628 668 18 34 Down Down Up Up Down Up Down Up Down

Belgium 57,849 9,388 137 230 Down Down Down Down Down Down Up Down Down

Brazil 438,238 26,754 16,324 17,085 Down Up Up Up Up Down Up Up Up

Canada 89,976 6,982 941 1,062 Down Down Down Down Down Down Up Up Up

China 84,106 4,638 3 6 Down Down Down Down Down Down Down Up Down

Croatia 2,245 102 0 1 Down Down Down Down Down Up Down Up Up

Denmark 11,712 568 52 52 Up Up Down Up Up Up Down Up Up

Estonia 1,851 66 6 7 Down Down Up Down Down Down Down Down Down

Finland 6,743 313 64 36 Up Down Down Up Up Down Down Up Down

France 186,364 28,665 148 220 Down Down Down Up Up Down Down Up Up

Germany 182,450 8,472 353 424 Down Up Up Up Down Down Down Up Up

Greece 2,906 175 11 8 Up Down Up Up Up Down Down Down Down

Hungary 3,841 517 23 25 Down Up Up Down Down Up Down Up Down

Iceland 1,805 10 1 0 Up Up Up Up Up Down Down Down Up

India 165,829 4,713 6,566 6,568 Down Up Up Up Up Up Down Down Down

Ireland 24,841 1,639 68 70 Down Down Down Down Down Up Up Up Down

Israel 16,887 284 28 16 Up Down Up Down Down Up Down Down Up

Italy 231,732 33,142 584 539 Up Down Down Down Down Up Down Down Down

Japan 16,620 881 32 37 Down Down Down Down Down Down Down Up Up

Korea 11,402 269 79 32 Up Down Up Down Down Down Down Down Down

Lithuania 1,656 68 8 10 Down Up Up Down Down Down Down Down Up

Luxembourg 4,008 110 6 4 Up Up Up Down Up Down Up Down Up

Malaysia 7,629 115 15 87 Down Down Down Down Up Down Down Down Down

Netherlands 46,152 5,922 190 189 Up Up Down Down Down Down Down Down Down

Norway 8,411 236 19 16 Up Down Down Up Up Up Up Down Down

Philippines 15,588 921 380 261 Up Up Up Up Up Down Up Down Down

Portugal 31,596 1,369 285 230 Up Up Down Up Down Down Down Down Up

Russia 379,051 4,142 8,371 8,785 Down Down Down Up Up Down Up Up Up

Singapore 33,860 23 533 502 Up Down Down Up Down Up Up Up Up

Slovenia 1,473 108 2 6 Down Up Up Down Up Down Up Up Down

Spain 237,906 27,119 510 655 Down Down Down Down Down Down Up Down Down

Sweden 35,727 4,266 648 509 Up Up Up Up Up Up Down Up Up

Switzerland 30,796 1,919 15 17 Down Up Down Down Down Down Up Down Down

Thailand 3,076 57 11 4 Up Up Down Down Down Down Down Down Down

Turkey 160,979 4,461 1,035 1,030 Up Down Up Up Up Down Down Up Up

UK 270,508 37,919 2,013 2,707 Down Down Down Up Down Down Down Up Up

US 1,721,750 101,617 24,886 22,431 Up Up Down Down Down Down Down Up Up


• This COVID-19 Active Cases Curve Simulator has been developed by the IQVIA Data Science and Advanced Analytics team as a tool to

help stakeholders make decisions based on the level and trajectory of active cases in their country, region or state

• The core of the model is the Susceptible-Exposed-Infectious-Removed epidemiology model, and inputs are from publicly available

sources updated daily

• The simulator focuses on “total active cases” as a metric that speaks to the overall impact COVID-19 is having, not just limited to

hospitalizations or deaths (where other models are focused, e.g. IHME). We believe the active cases curve will be used by public health

officials – along with other considerations, such as availability of testing – to guide their decision- making on modifying stay-at-home rules

• Active cases are those confirmed diagnosed cases, excluded those that have recovered or died.

• The simulation shows the number of active cases (per population), shape of increase of the curve, timing of the apex of the curve and the

shape and timing of the decline from the apex.

• Scenarios are labelled as “normal”, “optimistic” and “pessimistic” based on the following

• “Normal” scenario means the model parameters are derived to fit most closely to the actual reported public data

• “Optimistic” scenario is the lower bound, assuming people closely follow nonpharmaceutical interventions (NPIs), and reference what was

achieved in other countries with similar characteristics

• “Pessimistic” scenario is the upper bound, assuming people do not closely follow NPIs and time from exposure to diagnosis takes longer

than reported in the literature

Cases Curve Simulator

Source: IQVIA, April 2020


Simulation band of active cases in next 150 days in U.S.

Source: IQVIA, May27, 2020

Projected total

confirmed cases

Projected total

confirmed cases

per 100k

population

Estimated

Peak time

Optimistic

Scenario1.8M 558.3 5/27/2020

Normal

Scenario2.9M 889.3 5/30/2020

Pessimistic

Scenario3.5M 1072.7 6/5/2020


Simulation of active cases per 100k population in next 150 days in US



Simulation band of active cases in next 150 days in Italy

Projected Total

Confirmed

Cases

Projected total

confirmed

cases per 100K

population

Estimated peak

time

Optimistic

Scenario233.2K 388.6 4/19/2020

Normal

Scenario243.8K 406.3 4/19/2020

Pessimistic

Scenario270.2K 450.3 4/19/2020



Simulation band of active cases in next 150 days in Germany

Projected

Total

Confirmed

Cases

Projected Total

Confirmed

Cases per 100k

Population

Estimated

Peak Time

Optimistic

Scenario185.2K 222.7 04/06/2020

Normal

Scenario186.8K 224.7 04/06/2020

Pessimistic

Scenario189.0K 227.3 04/06/2020



Simulation band of severe active cases in next 150 days in UK

Projected

Total

Severe

Confirmed

Cases

Projected

Total Severe

Confirmed

Cases per

100kPopulation

Estimated

Peak Time

Optimistic

Scenario285.6K 429.9 05/07/2020

Normal

Scenario295.8K 445.2 05/07/2020

Pessimistic

Scenario311.5K 468.9 05/07/2020



Simulation band of active cases in next 150 days in Spain

Projected

Total

Confirmed

Cases

Projected Total

Confirmed

Cases per 100k

Population

Estimated

Peak Time

Optimistic

Scenario240.1K 516.3 04/17/2020

Normal

Scenario247.7K 532.7 04/17/2020

Pessimistic

Scenario261.7K 562.7 04/17/2020



• 28 May

• Oxford Biomedica penned a one-year clinical and commercial supply deal with AstraZeneca to scale up manufacturing for the COVID-19 vaccine candidate AZD1222.

• Roche announced a new partnership with Gilead as the drugmakers started a phase III study testing the Swiss drugmaker's immunology med Actemra/RoActemra alongside Gilead's antiviral

remdesivir to treat COVID-19. Roche plans to begin enrollment in June, with a target of 450 patients globally.

• Moderna expanded a 2016 deal with Swiss pharmaceutical ingredient maker CordenPharma on Thursday to secure large quantities of lipids for its experimental COVID-19 vaccine mRNA-

1273. The deal grants access to two additional CordenPharma manufacturing sites in France and the U.S. as Moderna looks to boost its vaccine stores in anticipation of success in the clinic.

• GlaxoSmithKline (GSK) has announced it will manufacture one billion doses of its pandemic adjuvant by 2020.

Although GSK is not producing its own Covid-19 vaccine, it is supporting on a non-profit basis other companies who are with its pandemic adjuvant. During previous flu pandemic, this part of

the vaccine, which boosts the immune response, was shown to reduce the amount of protein needed per dose, therefore allowing more doses to be produced.

• 27 May

• The World Health Organization is putting a stop to global studies into the effectiveness of hydroxychloroquine after repeated safety concerns. The decision came following a study published

in The Lancet that showed patients who took hydroxychloroquine were at higher risk of death and heart problems than those who did not.

• 26 May

• Gilead's remdesivir has shown promising results, but some limits, too. Detailed data published in the New England Journal of Medicine showed that on average, hospitalized patients

receiving remdesivir recovered a median of four days faster than patients on placebo, with mortality in the remdesivir group at 7.1% compared to the placebo group's 11.9%. But the data also

suggest the drug offers more benefits to patients on oxygen therapy than to the critically ill on mechanical ventilators.

• The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted early access to remdesivir in its medicines scheme for conditions with a high unmet medical need.

• 25 May

• Like all industries, the pharma industry has been disrupted by the Covid-19 pandemic. The generics industry has been impacted particularly by supply chain problems and huge surges in

demand for existing medicines.

• Accord’s head of scientific affairs Dr Anthony Grosso explains how the industry has worked to overcome these challenges and respond to the needs of patients, as well as become more

prepared for future healthcare emergencies.

• 24 May

• Experts across world continue to highlight the need to reopen economies to limit the economic upheaval caused by the Covid-19 pandemic.

• However, some believe that unless testing capabilities are ramped up, reopening the economy may result in an upsurge in infection rate.

The latest coronavirus updates and developments impacting the global

pharmaceutical supply chain…


Pandemics – Number of Deaths

Source: Expresso - https://expresso.pt/coronavirus/2020-05-15-Covid-19.-O-maior-aumento-de-novos-casos-dos-ultimos-sete-dias-o-surto-em-Portugal--em-graficos-e-mapas-

https://expresso.pt/coronavirus/2020-05-15-Covid-19.-O-maior-aumento-de-novos-casos-dos-ultimos-sete-dias-o-surto-em-Portugal--em-graficos-e-mapas-


• 22 May

• Beximco Pharma launches first generic remdesivir for Covid-19, under the brand name Bemsivir.

• 21 May

• AstraZeneca has secured over $1 billion from the HHS' BARDA for the development and supply of the Oxford University vaccine it has partnered on.

• Moderna is currently the leader in the mRNA vaccine space, but Evercore ISI analyst Umer Raffat is raising doubts about the strength of the preliminary phase 1 data the biotech recently

posted.

• AstraZeneca has previously also invested in Moderna.

• The unemployment rate in the US currently stands at 14.7% but for people aged between 20 and 24, the rate increases to 25.7%, according to statistics provided by the BLS.

• 20 May

• People with Type 1 diabetes are three and a half times more likely to die than non-diabetics who catch COVID-19 while Type 2 patients are twice as likely to die than non-diabetics, NHS

England has found.

• 19 May

• Gilead Sciences has pledged to donate its current supply of 1.5 million doses of remdesivir, of which 607,000 vials are being allocated to the U.S. government. Now, the biotech is increasing

its U.S. donation to about 940,000 doses by June.

• The Trump administration has signed a $354 million four-year deal with with a new Virginia company called Phlow to produce generic drugs and APIs needed to treat COVID-19 in an effort

to bring pharma manufacturing back to the U.S.

• Meanwhile, Cipla, which is one of four drugmakers with nonexclusive remdesivir licensing deals, is also looking at combo treatment options for COVID-19, including teaming Fujifilm's flu drug

Avigan (favipiravir) with the Gilead med.

• 18 May

• Moderna shares leapt as the company unveiled early phase 1 data showing its vaccine candidate, mRNA-1273, elicited neutralizing antibodies in eight trial participants available for analysis.

Based on the data, The company said its own phase 2 trial will be amended to study two dose levels, 50 µg and 100 µg.

• On the heels of unveiling early results for its mRNA vaccine, Moderna plans to raise $1.34 billion through a stock sale to help produce the shot if it crosses the regulatory finish line.

• Moncef Slaoui, the newly appointed U.S. coronavirus czar, will divest his $10 million in Moderna stock options, which shot up in value Monday after the company unveiled promising early

data.

• 17 May

• The EU could grant Gilead's remdesivir an conditional nod in the "coming days," EMA head Guido Rasi said on Monday at a hearing at the EU Parliament in Brussels.


pharmaceutical supply chain… (cont.)


• 14 May

• After a fast-tracked approval, Japan has already started distributing Gilead Sciences' remdesivir to hospitals. The drug is being used for patients in intensive care or on ventilators.

• The United Nations’s International Labour Organization predicts 1.6bn informal economy workers could suffer “massive damage” to their livelihoods.

• In the second quarter of 2020, Covid-19 may cost the equivalent of 305 million full-time jobs.

• Current G7 jobless totals vary widely, from 30 million in the United States to 1.76 million in Japan.

• McKinsey believe that Europe’s CEOs will have to draw on the region’s spirit of innovation to recover post Covid-19.

• 13 May

• The US Food and Drug Administration (FDA) has granted fast track designation to Moderna’s Covid-19 vaccine candidate, mRNA-1273.

• Even if Moderna succeeds with its unproven vaccine platform, the biotech won't be able to make enough doses for the entire world, CEO Stephane Bancel said.

• After Gilead inked a series of licensing deals for remdesivir, Public Citizen argued the drug should be in the public domain.

• 12 May

• Gilead inked licensing deals with generic drugmakers Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan allowing those companies to manufacture and distribute

remdesivir in 127 countries, royalty-free.

• The European Medicines Agency expanded its compassionate use guidelines for Gilead's remdesivir. Originally, the drug was recommended for patients requiring mechanical ventilation. It's

now recommended for certain hospitalized patients.

• 11 May

• Physicians and hospitals have already expressed frustrations about the difficulty obtaining Gilead Sciences' remdesivir. Now, an HHS distribution plan shows that only 607,000 vials of the

emergency use drug will be made available to U.S. patients over the next six weeks, out of a total donation of about 1.5 million

• 9 May

• Gilead Sciences may have been the target of Iranian hackers using fake email login pages to access confidential data, Reuters reported. In one case, a fake login page was sent to a legal

and corporate affairs executive in April. Reuters couldn't confirm whether the attack was successful.

• Speaking of Gilead, the National Institutes of Health will pair the drugmaker's COVID-19 antiviral remdesivir with Eli Lilly's rheumatoid arthritis drug Olumiant in a new study in U.S.

hospitalized patients. The trial will eventually enroll 1,000 patients across 100 sites, the NIH said.

• After the FDA's emergency use authorization, Gilead donated its entire stockpile of remdesivir to the government for further distribution. But the drug hasn't reached those most in need,

according to Axios. "Some went to the wrong places, some went to the right places," one senior Trump administration official said. "We don't know who gave the order. And no one is claiming

responsibility."




• 8 May

• Hydroxychloroquine has failed an observational study in New York. According to a paper published in The New England Journal of Medicine, researchers found no significant difference

between hydroxychloroquine and standard care in terms of patients' need for ventilation or death rate.

• After the FDA's emergency use authoriziation, Gilead has donated its entire stockpile of remdesivir to the government for further distribution.

• FDA authorises Moderna to conduct Phase II trial of Covid-19 vaccine

• 7 May

• Gilead Sciences' remdesivir won approval in Japan as Veklury. It's the first full global nod for the COVID-19 treatment following the U.S. emergency use authorization last week. Authorities in

Japan approved the drug under an "exceptional approval" regulatory pathway.

• Gilead spent about $50 million on remdesivir manufacturing scale-up and clinical trial costs during the first quarter.

• Moderna is planning an "imminent" start to a 600-participant phase 2 trial of its mRNA vaccine candidate, mRNA-1273, after the FDA cleared its trial protocol. The company's goal is to

initiate a phase 3 study "early this summer" and win approval as soon as 2021.

• 6 May

• Gilead Sciences says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe,

Asia and beyond until at least 2022.

• Scientists have identified a new strain of the coronavirus that appears to be more contagious than the early versions in the pandemic, according to a new study led by scientists at Los

Alamos National Laboratory.

• 5 May

• A drugmaker in Bangladesh, Beximco, plans to start making Gilead's newly FDA-authorized remdesivir for $59 to $71 per vial, Reuters reports. The company is planning to produce the drug

for domestic use, at least initially. It isn't clear whether Beximco had a licensing deal to manufacture the product.

• 4 May

• How much should Gilead Sciences charge for remdesivir? Up to $4,460 per patient, according to the Institute for Clinical and Economic Review. But even at $1,000 per patient—less than a

quarter of ICER's pitched price—Gilead could theoretically rake in $1 billion in sales, as it looks to build a supply capable of treating 1 million patients by the end of the year.

• 2 May

• Moderna Therapeutics has tapped Lonza to help manufacture the biotech's mRNA vaccine candidate, dubbed mRNA-1273.




• 30 April

• Economic Outlook: Covid-19 puts 1.6 billion jobs at risk – Q1 company earnings ‘most watched in history’ say Goldman Sachs.

• GDP of majority of the economies to be below pre-Covid-19 levels for two to three years.

• Gilead’s remdesivir meets endpoint in NIAID study.

• GlobalData Epidemiologist Report – Covid-19 now affects 187 countries – over 1 million cases in US

• 29 April

• The US economy has contracted at an annual rate of 4.8%, the steepest slump since the 2008 recession. This brings the longest ever period of economic expansion in the US to an end.

• It is predicted that gross domestic product (GDP) could drop by 30% in the next quarter, as many “stay-at-home” measures were only implemented at the end of this quarter, with a sharp

rise in unemployment also anticipated.

• 28 April

• On the back of disappointing results for Sanofi and Regeneron’s IL-6 inhibitor, Kevzara yesterday, a research team from the Assistance Publique-Hôpitaux de Paris announced that an open-

label, randomized, controlled study of Roche’s Actemra in 129 moderate to severe COVID-19 patients with pneumonia was successful.

• UK Approves Clinical Trial Of Plasma Therapy for COVID-19.

• Covid-19’s impact on drug contract manufacture in Italy. GlobalData’s Contract Service Provider database shows there are 148 CMOs with Italian facilities

• 27 April

• Another high profile drug being repurposed for COVID-19 treatment faced a major setback this morning. Sanofi and Regeneron’s IL-6 inhibitor, Kevzara showed no benefit in “severe”

COVID-19 patients requiring oxygen therapy.

• China has granted approval to assess a third coronavirus vaccine candidate against COVID-19 in the second phase of clinical trials.

• Vaccine major Serum Institute of India on Sunday said it plans to start production of the COVID-19 vaccine developed by Oxford University in the next two to three weeks and hopes to bring

it to the market by October if the human clinical trials are successful.

• France, Italy and Spain announce easing of lockdown measures.

• 24 April

• On April 23rd, news broke of a potential failure of Gilead's COVID-19 candidate, remdesivir, to improve mortality in hospitalized adult patients with severe COVID-19 from a trial in China.

However, any data reported here must be approached with caution, as the full results of the study have not yet been made available, and what has been released is from a trial which was

terminated due to difficulties in recruitment.




• 23 April

• Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the WHO accidentally posted on its website.

• Preliminary reports from epidemiological studies suggest that countries with universal BCG vaccination programs have been impacted less by Covid-19

• 22 April

• The Covid-19 pandemic is expected to widen the gap between the poor and rich creating massive inequality and high unemployment rates.

• The world is on track for a recession of “unprecedented depth in the post-war period”, ratings agency Fitch says with world gross domestic product to tumble by 3.9% in 2020.

• 21 April

• Pharma CEOs are asking that governments pour out billions of dollars in advance for the development and production of potential COVID-19 drugs.

• Following other companies such as Pfizer and Novo Nordisk, Merck & Co. is now also expanding its patient assistance program, allowing eligible patients to get its medicines at no cost.

• To ease shortages of drugs for COVID-19 patients who are on ventilators, the FDA is now allowing small compound pharmacies to temporarily fill the supply gap.

• 20 April

• Researchers at the NIH and Gilead have published results from an animal trial of remdesivir, involving 12 rhesus macaques, showing that early antivrial treatment reduced COVID-19

symptoms and lung damage.

• Though the COVID-19 pandemic has upended the public markets—and thrown a wrench into what was expected to be a stellar IPO season—the biotech industry could be that particular

cloud’s silver lining, as investors look toward additional windows and opportunities later this year.

• A congressman is calling on the SEC to investigate last week’s leak of remdesivir data, along with its impact on the stock market and a 15% boost in Gilead’s share price. Though the

antiviral is not supposed to be a moneymaker for the Big Pharma, news following its development has added billions to Gilead’s market cap.

• The FDA has granted emergency use authorizations to four antibody diagnostics—also known as serology tests—that promise to help identify individuals who have been exposed to the

novel coronavirus.

• 19 April

• Meanwhile, in the U.S., the FDA has stepped up seizures of prescription drugs being sent to American customers from Canada and other countries, where they are sold at cheaper prices,

according to Kaiser Health News.

• 18 April

• In the European region, it’s notable that the number of cases are increasing in Belgium with a total of 34,809 cases, placing the country in rank just after the UK, though the gap between the

two countries is large.




• 17 April

• BARDA supports Moderna’s vaccine.

• Promise of Gilead’s remdesivir made clear.

• Nasal spray vaccine on the horizon.

• 16 April

• Millions of doses of hydroxychloroquine donated to the U.S. by Bayer have come under scrutiny after the quality of the drug's Indian and Pakistani active pharmaceutical ingredients and

finished doses may have never passed FDA inspections, sources told Reuters. Bayer has donated 3 million tablets of the drug, called Resochin, to the U.S. national stockpile for treatment of

COVID-19.

• Despite the fact that Fujifilm's Avigan hasn't been proven as an effective COVID-19 treatment, Japan and China are providing the drug to other countries, the Wall Street Journal reports.

• 15 April

• India is hoping to rapidly expand its production of global active pharmaceutical ingredients to compete with China's dominance in the market amid COVID-19 lockdowns, Bloomberg reported.

The country is one of the largest providers of generic drugs to the U.S.

• Gilead Sciences is among the companies with promising COVID-19 drugs and the company has now applied for a trademark for potential remdesivir packaging. But at press time, the

company's shares were down on word that a second China trial had been stopped for lack of enrollment.

• As the White House's Tuesday press briefing, President Donald Trump said the U.S. is halting funding to the World Health Organization. Bill Gates and others blasted the move.

• 14 April

• China's National Medical Products Administration has greenlit two inactivated COVID-19 vaccines to start human testings.

• Sanofi and GSK, two of the world’s biggest vaccine makers, are joining forces to develop a recombinant DNA vaccine, aiming to enter clinical testing in the second half of 2020.

• 13 April

• Rutgers University has received the FDA’s first emergency authorization for a COVID-19 diagnostic that uses easy-to-collect saliva samples instead of the more difficult deep nose swabs.

• Gilead provided results from 53 severe COVID-19 patients treated with remdesivir on a compassionate use basis in a paper published in The New England Journal of Medicine. During a

median follow-up of 18 days, 36 patients (68%) had a clinical improvement, and the mortality rate was 18% among patients receiving invasive ventilation. Jefferies analysts argue the data

"suggest remdesivir may work and is generally safe."

• 10 April

• Gilead's promising COVID-19 drug candidate remdesivir could be made at $9 per treatment, while the estimated manufacturing cost for generic hydroxychloroquine stands as little as $1 per

course, a study published in the Journal of Virus Eradication found.




• 9 April

• Pfizer says a Phase 2 investigator-initiated study for the use of tofacitinib, a JAK inhibitor, in patients with SARS-CoV-2 interstitial pneumonia is about to start in Italy.

• Mylan says its expedited manufacturing of hydroxychloroquine has resulted in stocks being available ahead of schedule.

• Analysts at Morningstar say the coronavirus pandemic will affect Big Pharma and Big Biotech companies in two major ways: an economic slowdown, likely causing a 4.6% hit to 2020 global

GDP (implying a 1.4% decline in 2020), and a disruption in the use of drugs, vaccines, and consumer healthcare products. “However, the highly inelastic demand for most drugs should

largely offset any recessionary impact,” they add.

• 8 April

• The European Commission publishes its guidelines on the optimal and rational supply of medicines to avoid shortages during the COVID-19 outbreak.

• US Food and Drug Administration commissioner Stephen Hahn says that since the agency issued its policy to allow developers of serological tests to identify patients that have developed an

immune response to market them without FDA review, over 70 tests are available for use.

• 7 April

• Bristol Myers Squibb announces an expansion of its patient support programs to help unemployed US patients who have lost their health insurance due to the COVID-19 pandemic.

• 6 April

• India lifts export restrictions on 12 APIs and their formulations including antibiotics, vitamins and hormones with immediate effect, according to a Directorate General of Foreign Trade

notification. Paracetamol and hydroxychloroquine are notable omissions from the list.

• Thermo Fisher Scientific says that due to the COVID-19 pandemic, it is withdrawing its 2020 annual financial guidance, which was provided on January 30. “As the pandemic spread from

China to countries worldwide, the company saw a significant reduction in customer activity by late March.

• 4 April

• In an open letter, Gilead CEO Daniel O’Day says the biotech company has managed to reduce the end-to-end manufacturing timeline for its antiviral remdesivir – which has shown potential

to treat patients with severe COVID-19 -- from one year to around six months.

• India’s Directorate General of Foreign Trade announces an immediate blanket ban on exports of hydroxychloroquine “without any exceptions.”




• 3 April

• Generics industry association Medicines for Europe supports a call by the European University Hospital Alliance for European coordinated efforts to prevent shortages of ICU medicines –

which include sedatives, muscle relaxants, antibiotics and anaesthetics -- amid rising demand.

• Novartis says it plans to start a clinical trial of its JAK inhibitor, Jakavi (ruxolitinib), in patients with COVID-19 associated cytokine storm, a form of severe immune overreaction that can result

from coronavirus infection.

• 2 April

• Roche Canada announces its COVID-19 Innovation Challenge, a competition to bring forward innovative ideas to fight the pandemic.

• Amgen and Adaptive Biotechnologies announce a partnership to develop neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.

• The US Food and Drug Administration approves Celularity’s Investigational New Drug application for its CYNK-001 cell therapy in adults with COVID-19.

• The European Medicines Agency says chloroquine and hydroxychloroquine, currently authorised for malaria and certain autoimmune diseases but being investigated for their potential to

treat COVID-19, should only be used in clinical trials or emergency use programmes.

• 1 April

• AbbVie is donating USD35 million to support COVID-19 relief efforts.

• Gilead announces that it has started two Phase 3 studies of its investigational antiviral treatment, remdesivir, in patients with moderate to severe COVID-19 in the UK.

• The US Food and Drug Administration says it has launched a program to speed up the development of treatments for COVID-19.

• 31 March

• The US government is in discussions with India over a possible relaxing of restrictions on API exports from India imposed at the start of March.

• China is stepping up its efforts to produce and ship APIs with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease

• 30 March

• In a letter to customers, CordenPharma says it has halted routine manufacturing at its Bergamo facility in northern Italy for one week from 26 March to 1 April due to supply chain interruption

and staffing issues.

• Novartis announces that its generics unit Sandoz has started to ship 30 million doses of hydroxychloroquine to the US Department of Health and Human Services for use in clinical studies to

test its effectiveness in people who have tested positive for COVID-19.




• 27 March

• Sanofi and Translate Bio are collaborating to develop a novel mRNA vaccine candidate against COVID-19, extending an existing 2018 agreement between the two firms on mRNA vaccines

for infectious diseases.

• Wuxi Biologics says more than 98% of its staff are now back at work after the country’s recent lockdown. The Chinese CDMO says it has received “a surge of requests” in March for new

projects, predominantly from clients outside of China.

• 26 March

• The proposed merger Mylan and Pfizer’s generics division, Upjohn, is postponed until the second half of 2020 due to the COVID-19 pandemic. Mylan’s EGM has been pushed back two

months to 30 June.

• A consortium of fifteen biopharma companies have agreed to share their proprietary libraries of drugs that already have promising safety and activity data with the COVID-19 Therapeutics

Accelerator launched by the Gates Foundation, Wellcome, and Mastercard to quickly screen them for potential against COVID-19. The firms include BD, Boehringer Ingelheim, bioMerieux,

Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis, Pfizer and Sanofi.

• Mylan waives its right to a 180-day marketing exclusivity period in the US to distribute its generic version of antiretroviral Kaletra (lopinavir/ritonavir) to help increase the available supply of

the product should it prove effective in treating patients with COVID-19.

• 25 March

• Medicines for Europe says export restrictions (including some within the EU) on drug and ingredients manufacturers is undermining European production. The generics industry body says its

mid-February request for effective coordination between manufacturers and authorities to manage the crisis has not been fully realized. “We deeply regret that this process is not yet fully

operational at EU or at national level except in Italy,” it says.

• Vir Biotechnology announces that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19. The

firm expects human trials to begin within 3-5 months.

• Suven Pharmaceuticals warns customers it cannot export finished products due to a shortage of raw materials following India’s recent lockdown to fight COVID-19.Suven Pharmaceuticals

warns customers it cannot export finished products due to a shortage of raw materials following India’s recent lockdown to fight COVID-19.

• CDMO Catalent reaffirms it has not identified any significant risk or delay that may have a substantial effect on delivery of products or clinical trial supplies.




• 24 March

• Switzerland-headquartered CDMO Siegfried is supplying disinfectant in the Swiss and German regions where it operates production sites. It says it will not supply private or commercial

organizations.

• In a letter to customers, CDMO CordenPharma says it has instructed all employees to cancel all business travel and face-to-face meetings until the end of April. It says all its manufacturing

facilities in Italy, Germany, France, Switzerland and the US are fully operational.

• CMO Argonaut Manufacturing Services says it is ready to provide services for pre-clinical to Phase III manufacturing of vaccines and therapeutics, including those for firms working toward a

COVID-19 vaccine or therapeutic under accelerated timelines.

• 23 March

• The International Generic and Biosimilar medicines Association, representing generic and biosimilar manufacturers, urges governments to reopen air freight routes to ensure access to

medicines during the COVID-19 pandemic.

• Roche’s Genentech in collaboration with the Biomedical Advanced Research and Development Authority says the FDA has approved a Phase III clinical trial of its arthritis drug Actemra

(tocilizumab) to treat hospitalized adult patients with severe COVID-19 pneumonia.

• Eli Lilly becomes the first Big Pharma company to announce its clinical trials are being adversely affected by coronavirus. The firm says it is delaying most new study starts and pausing

enrollment of new patients or volunteers “to ease the burden on participating healthcare facilities.”

• 22 March

• Gilead says it is no longer accepting requests for emergency access to its antiviral remdesivir due to an “exponential increase” in such requests and “overwhelming demand.”

• 21 March

• The Indian government approves a USD1.8 billion scheme to boost production of APIs and medical devices. The plan involves development of three mega API drug parks in partnership with

states and financial incentives to manufacturers of 53 identified critical APIs on incremental sales for the next six years.

• In a filing to the Bombay Stock Exchange, Ipca Laboratories says the US FDA has lifted an import alert on its hydroxychloroquine sulphate and chloroquine phosphate APls and

hydroxychloroquine sulphate tablets due to the shortage implications of coronavirus.

• Bristol Myers Squibb says it has now implemented a mandatory work from home policy for its workforce. “All employees, contingent workers and contractors who can do their jobs from home

must do so,” it says.




• https://en.wikipedia.org/wiki/Timeline_of_the_2019%E2%80%9320_Wuhan_coronavirus_outbreak

• https://www.seattletimes.com/seattle-news/health/coronavirus-timeline-how-the-outbreak-unfolded/

• https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

• https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

• https://www.pharmaceutical-technology.com/news/coronavirus-a-timeline-of-how-the-deadly-outbreak-evolved/

• https://www.cphi-online.com/updated-covid19-pharma-tracker-news082415.html

• https://www.dgs.pt/em-destaque.aspx

Sources

https://en.wikipedia.org/wiki/Timeline_of_the_2019%E2%80%9320_Wuhan_coronavirus_outbreak

https://www.seattletimes.com/seattle-news/health/coronavirus-timeline-how-the-outbreak-unfolded/


https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

https://www.pharmaceutical-technology.com/news/coronavirus-a-timeline-of-how-the-deadly-outbreak-evolved/

https://www.cphi-online.com/updated-covid19-pharma-tracker-news082415.html

https://www.dgs.pt/em-destaque.aspx

josé luis pires sars-cov-2 report 29 may 2020 · 5/29/2020 · may 2020 confidential hovione ©...

Documents